Novo Nordisk has long been working on drugs that can help people earlier on in their diabetes and keep them from progressing to insulin treatment. But that doesn’t mean it’s not also working to ...

The designation means that pharmacists can switch patients to the less-expensive version of insulin without seeking approval from the clinician. The FDA late Thursday approved the country’s first ...

Please provide your email address to receive an email when new articles are posted on . The FDA approved the second interchangeable insulin glargine biosimilar, Rezvoglar, to improve glycemic control ...